Relation of higher folate intake to lower risk of Alzheimer disease in the elderly

Archives of Neurology

Volumn 64, Issue 1, 2007, Pages 86-92

  Luchsinger, José A ^a,c,e   Tang, Ming Xin ^a   Miller, Joshua ^d   Green, Ralph ^d   Mayeux, Richard ^a,b,c  

^a Columbia University ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; CALORIC INTAKE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIETARY INTAKE; ETHNICITY; FEMALE; FOLLOW UP; GENE FREQUENCY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; SUPPLEMENTATION; VITAMIN INTAKE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DIETARY SUPPLEMENTS; ENERGY INTAKE; FEMALE; FOLIC ACID; HUMANS; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK; VITAMIN B COMPLEX;

EID: 33846119171     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.1.86     Document Type: Article

References (59)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
2. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
3. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA. 2004;291:565-575.
4. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
5. Leboeuf R. Homocysteine and Alzheimer's disease. J Am Diet Assoc. 2003;103:304-307.
6. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
7. Mooijaart SP, Gussekloo J, Frolich M, et al. Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus study. Am J Clin Nutr. 2005;82:866-871.
8. 12 and folate in relation to the development of Alzheimer's disease. Neurology. 2001;56:1188-1194.
9. 12 intake and cognitive decline among community-dwelling older persons. Arch Neurol. 2005;62:641-645.
10. 12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med. 2005;118:161-167.
11. Tang MX, Stern Y, Marder K, et al. The APOE-ε4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751-755.
12. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49:453-460.
13. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol. 1986;124:17-27.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
15. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
17. Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology. 2003;60:1071-1076.
18. World Health Organization. CD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization; 1993.
19. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep. 2004;6:261-266.
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-548.
21. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37:254-259.
22. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981.
23. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
24. SAS/STAT User's Guide Version 8 [computer program]. Cary, NC: SAS Institute Inc; 1997.
25. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
26. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004;62:1972-1976.
27. Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000;283:1615-1617.
28. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-175.
29. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002;22:1752-1762.
30. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr. 2000;71:993-998.
31. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
32. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 2005;64:494-500.
33. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707-1712.
34. Seshadri S, Wolf PA. Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol. 2003;2:11.
35. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol. 2002;51:285-289.
36. He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35:169-174.
37. Basun H, Fratiglioni L, Winblad B. Cobalamin levels are not reduced in Alzheimer's disease: results from a population-based study. J Am Geriatr Soc. 1994;42:132-136.
38. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306-314.
39. Ebly EM, Schaefer JP, Campbell NR, Hogan DB. Folate status, vascular disease and cognition in elderly Canadians. Age Ageing. 1998;27:485-491.
40. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci. 1997;52:M76-M79.
41. Lindeman RD, Romero LJ, Koehler KM, et al. Serum vitamin B12, C and folate concentrations in the New Mexico Elder Health Survey: correlations with cognitive and affective functions. J Am Coll Nutr. 2000;19:68-76.
42. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol. 1999;150:283-289.
43. Elias MF, Sullivan LM, D'Agostino RB, et al. Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. Am J Epidemiol. 2005;162:644-653.
44. Tucker KL, Qiao N, Scott T, Rosenberg IH, Spiro AR. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr. 2005;82:627-635.
45. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc. 2005;53:381-388.
46. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL. Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology. 2004;63:254-260.
47. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636-643.
48. Miller JW, Green R, Ramos MI, et al. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2003;78:441-447.
49. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002;58:1471-1475.
50. Corrada MM, Kawas CH, Hallfrisch J, Muller D, Brookmeyer R. Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. Alzheimer Dement J Alzheimer Assoc. 2005;1:11-18.
51. Crystal HA, Ortof E, Frishman WH, Gruber A, Hershman D, Aronson M. Serum vitamin B12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc. 1994;42:933-936.
52. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry. 2001;16:609-614.
53. Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. Int J Geriatr Psychiatry. 2000;15:226-233.
54. Kwok T, Tang C, Woo J, Lai WK, Law LK, Pang CP. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry. 1998;13:611-616.
55. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 2004;3:579-587.
56. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol. 2006;59:912-921.
57. Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol. 2003;25:625-633.
58. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002;59:1258-1263.
59. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.